1. Anton Y. Peleg, M.B., B.S., M.P.H., and David C. Hooper, M.D. N Engl J Med 2010;362:1804-13 Hospital-Acquired Infections Due to Gram-Negative Bacteria R4 박소연

2. Hospital-acquired infections - in 2002, 4.5 /100 admissions, almost 99,000 deaths ( sixth leading cause of death in the United States) - costs to the U.S. health care budget :$5 billion to $10 billion annually Gram-negative bacteria that commonly cause hospital acquired infections

3. Figure 1. Mechanisms of Resistance in Gram-Negative Bacteria, and the Antibiotics Affected

4. Types of Infections 1. Pneumonia HAP - most common life-threatening hospital-acquired infection, the majority of cases are associated with mechanical ventilation (10 to 20% of patients who are on ventilators for longer than 48 hours) - a/w significant increases in length of hospital stay, mortality, costs - P. aeruginosa, A. baumannii, the Enterobacteriaceae - IRPA :26.4% of 679, IRAB 36.8% of 427 that caused VAP

5. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare- associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416 more likely - to have a coexisting illness - to receive inactive empirical antibiotic therapy - at greater risk for death  Antibiotics with a broader spectrum of coverage : P. aeruginosa, MDR gram-negative bacilli, and drug-resistant S.aureus

6. Appropriate time - sample from the lower respiratory tract by means of endotracheal aspiration, bronchoalveolar lavage, or a protected specimen brush for microscopy and culture Colonization vs. infection - quantitative cultures - biomarkers : procalcitonin, CRP,soluble triggering receptor expressed on myeloid cells (sTREM-1)

7. Table 3. Evidence-Based Guidelines for the Prevention of Hospital-Acquired Infections

8. Lower respiratory tract sample in KHMC 2009.01.01~2010.05.24Total Staphylococcus aureus14MRSA - 1 Acinetobacter baumannii10IRAB - 8 Klebsiella pneumoniae 7ESBL - 4 Pseudomonas aeruginosa5IRPA - 3 Streptococcus pneumoniae5 Enterobacter aerogenes3 others3 Total47

9. Bloodstream infection a/w the presence of a central vascular catheter, lung, genitourinary tract, or abdomen 30% of hospital-acquired bloodstream infections in ICUs in the United States are due to gram-negative organisms m/c klebsiella species, Escherichia coli, enterobacter species, and P. aeruginosa Drug Resistance - Klebsiella pneumoniae, 27.1% (from 483 isolates tested) were resistant to third- generation cephalosporins and 10.8%(from 452 isolates tested) were resistant to carbapenems - carbapenemase-producing Enterobacteriaceae: K. pneumoniae carbapenemase (KPC) confers reduced susceptibility to all cephalosporins(including cefepime), monobactams (aztreonam), and the carbapenems Types of Infections 2. Bloodstream Infection

10. Treatment – Empirical antibiotic coverage for gram-negative bacteria 1) immunosuppressed 2) those in the ICU 3) those with a femoral catheter 4) those with gram-negative bacterial infection at another anatomical site (particularly the lung, genitourinary tract, or abdomen) 5) those with other risk factors for resistant organisms Types of Infections 2. Bloodstream Infection

12. Table 3. Evidence-Based Guidelines for the Prevention of Hospital-Acquired Infections

13. Almost a/w urethral catheterization, asymptomatic After the second day of catheterization: the risk of bacteriuria increases by 5 to 10% per day the most effective management is removal of the catheter rather than antibiotic treatment - undergo urologic surgery or implantation of a prosthesis E. coli, P. aeruginosa, klebsiella species, enterobacter species,A. baumannii resistance to quinolones and extended- spectrum cephalosporins the SHVtype and TEM-type ESBLs have predominated among hospital- acquired organisms, and CTXM–type (CTX-M-15) ESBLs are becoming more common worldwide Types of Infections 3. Urinary Tract Infection

14. Table 3. Evidence-Based Guidelines for the Prevention of Hospital-Acquired Infections

15. 1) Polymyxins (colistin and polymyxin B) - Discovered in the late 1940s, have specificity for lipopolysaccharides on the outer cell membrane of gram-negative bacteria - Organisms inherently resistant to polymyxins : serratia, proteus, Stenotrophomonas maltophilia, Burkholderia cepacia, flavobacterium - key therapeutic option for carbapenem-resistant organisms, particularly P. aeruginosa, A. baumannii, and carbapenemase-producing Enterobacteriaceae - challenge to determine the appropriate dosage, since the polymyxins were never subjected to the rigorous drug-development process - antimicrobial activity is dependent on the peak blood concentration: two to four divided doses per day are currently recommended Types of Infections 4. Treatment Options

16. 2) Tigecycline - Parenteral glycylcycline, is approved for the treatment of complicated skin, soft-tissue, and intraabdominal infections - In vitro activity : ESBL-producing and carbapenemase-producing Enterobacteriaceae, acinetobacter species, and Stenotrophomonas maltophilia (P. aeruginosa and proteus species are intrinsically resistant to the drug) - Clinical experience with treating these multidrug-resistant bacteria remains limited (1) not suitable for the treatment of urinary tract infections (2) shown to be inferior to imipenem–cilastatin for the treatment of ventilator- associated pneumonia in a randomized, double-blind trial (3) rapid movement from the bloodstream into tissues after administration, peak tigecycline serum levels are low (0.63 μg per milliliter) with standard dosing (a 100-mg loading dose followed by 50 mg every 12 hours)  use for bloodstream infection due to organisms with a MIC of 1 μg/ml or more also remains limited and requires caution Types of Infections 4. Treatment Options

17. 3) combination therapy versus monotherapy (1) Empirical treatment: need to be tailored to local susceptibility data, because the benefits can be lost in the presence of high cross-resistance (e.g. fluoroquinolones and third-generation cephalosporins) (2) When the antibiotic susceptibilities of the infecting organism are known, monotherapy and combination therapy have similar outcomes, including rates of emergence of resistance and recurrence of infection (3) Exceptions : monotherapy with aminoglycosides for P. aeruginosa, which is inferior to any other monotherapy regimen, and possibly monotherapy for patients who have cystic fibrosis (4) recommend institution-tailored combination therapy for the empirical treatment of serious hospital-acquired gram-negative infections, followed by de-escalation to monotherapy once susceptibilities have been determined Types of Infections 4. Treatment Options

18. 4) Infusion methods for the treatment of VAP - prolonged infusion (3 to 4 hours) or continuous infusion of β-lactams - prolonging the infusion of β-lactams (cefepime, piperacillin–tazobactam) and the carbapenems significantly improves bactericidal target attainment - i.e., time above the minimum inhibitory concentration for at least 50% for cefepime and piperacillin–tazobactam and 40% for the carbapenems), especially for organisms with an elevated minimum inhibitory concentration (8 to 16 μg/ml) Types of Infections 4. Treatment Options

19. Aerosolized antibiotics Nebulized antibiotics (tobramycin, amikacin, and colistimethate sodium ) : to minimize systemic toxicity and improve drug delivery at the site of infection - For severe or refractory cases of pneumonia or those caused by highly drug- resistant organisms, nebulized antibiotics given as an adjunct to systemic antibiotics should be thought of as a therapeutic option - Respiratory toxicity such as bronchospasm has been reported and may be diminished or prevented by the administration of bronchodilators before dosing Types of Infections 4. Treatment Options